Ignite Creation Date:
2025-12-24 @ 10:49 PM
Ignite Modification Date:
2026-01-02 @ 7:26 PM
Study NCT ID:
NCT03801369
Status:
TERMINATED
Last Update Posted:
2025-11-21
First Post:
2019-01-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
Sponsor:
Gordon Mills, MD, PhD
Organization:
Study Modules
Identification Module
Status Module
Sponsor Collaborators Module
Oversight Module
Description Module
Conditions Module
Design Module
Arms Interventions Module
Outcomes Module
Eligibility Module
Contacts Locations Module
References Module
Adverse Events Module
Baseline Characteristics Module
Participant Flow Module